Sector revisions Johnson & Johnson

Equities

Market Closed - Nyse Other stock markets 04:00:02 2026-01-14 pm EST			5-day change	1st Jan Change
218.55 ^USD	+2.29%		+5.33%	+5.61%

Jan. 14	Tecvayli monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide	RE
Jan. 14	Johnson & Johnson Reports 71% Risk Reduction for Tecvayli in Phase 3 Myeloma Study	MT

Sector:

Location:

X axis:

Main competitors

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	1m. Revenue rev.	4m. EPS revision	4m. Revenue rev.	1y. EPS revision	1y. Revenue rev.	Visibility	Nbr of analysts
	JOHNSON & JOHNSON							24
	ELI LILLY AND COMPANY							27
	ABBVIE INC.							27
	ROCHE HOLDING AG							18
	ASTRAZENECA PLC							19
	NOVARTIS AG							19
	MERCK & CO., INC.							27
	NOVO NORDISK A/S							20
	AMGEN INC.							27
	GILEAD SCIENCES, INC.							26
	PFIZER INC.							24
	VERTEX PHARMACEUTICALS INCORPORATED							25
	SANOFI							21
	BRISTOL-MYERS SQUIBB COMPANY							23
	GSK PLC							18
	CHUGAI PHARMACEUTICAL CO., LTD.							14
	JIANGSU HENGRUI PHARMACEUTICALS CO.,LTD							17
	TAKEDA PHARMACEUTICAL COMPANY LIMITED							15
	ALNYLAM PHARMACEUTICALS, INC.							25
	Average							22
	Weighted average by Cap.							23